Hospital

More drugs plus a growing population of older and sicker patients is creating medication-alert overload for already stressed clinicians.

The bacteria were shown to contain a membrane-bound organelle structure that is like those found in eukaryotic cells.

This is the first trial to show that a measurable residual disease (MRD)–guided approach with treatment beyond MRD negativity has a significant advantage over chemotherapy, both in terms of progression-free survival and overall survival.

The study results shine a light on the potential need for further policy changes that promote gender equity and bridge the gap in R01 funding awarded to female applicants.

The efficacy of treatments, which is the outcomes in the ideal clinical trial setting, are known to often be better than the effectiveness of those treatments, which are the outcomes of patients in the real-world setting.

The study findings have implications for the identification of novel pathways with which to selectively target folate-metabolism blood cancers.

Study results indicate insignificant differences between PFS and OS in patients with HR[+]/HER2[-] breast cancer who received either palbociclib-letrozole or palbociclib-fulvestrant treatment.

This FDA approval represents the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years of age and older.

As the use of sequencing, proteomics, and immunopeptidomics increases, more targets will also be discovered, as well as more biomarkers that predict responses to treatments.

The study authors note that stress conditions result in an increased activity of the protein HDAC8, which promotes melanoma cell survival.

The study authors note that addressing environmental factors, such as IPV and food insecurity, can provide further benefits in neurodevelopment regardless of maternal HIV status.

Improvements in PFS were also seen among patients with brain metastases.

pCR rates were improved with the addition of pembrolizumab regardless of whether patients received the full chemotherapy doses.

MONARCH 3 final OS data show that the combination of abemaciclib and a NSAI in the first-line resulted in numerically longer OS compared to an NSAI alone.

Individuals with HR+ breast cancer could pause endocrine therapy for up to 2 years to become pregnant, without increasing the risk of recurrence.

Patients with an estrogen receptor measure greater than 8% and those with little to no TIL expression showed no benefit with the addition of nivolumab.

The investigational combination also delayed the median time to first chemotherapy in all age groups.

During clinical trials, individuals treated with iptacopan had increased hemoglobin levels and did not need to receive blood transfusions.

Patients with breast cancer who underwent chemotherapy and skipped RNI did not face an increased risk of disease recurrence or death 5 years post-surgery.

Although PFS was improved in patients with unresectable locally advanced or metastatic HER2-positive breast cancer, OS data were immature, requiring further research.

Trastuzumab deruxtecan and elacestrant both represent important new treatment options for subgroups of patients with breast cancer.

In the first-line setting, inavolisib plus palbociclib and fulvestrant improved PFS in patients with HR-positive breast cancers; however, further research is needed to understand the trends in OS.

The approval marks levothyroxine sodium as the only FDA-granted LT4 therapy that does not have a labeled interaction with PPIs and can be taken 15 minutes prior to eating breakfast.

These patients have slow brain wave activity during wakefulness, which can reduce the firing of nerve cells to protect against the pathology of epilepsy.

Chia seeds are a nutrient dense product that are rich in fiber and omega-3 fatty acids, and could have a hypocholesterolemic effect when ingested.

Currently, there is no established standard of care treatment approach of HGBL, with frontline interventions consisting of chemo-immunotherapies.

Investigators found that positive antiphospholipid antibodies and traditional risk factors were associated with atherosclerotic cardiovascular disease.

The study authors note that additional policies to reduce structural stigma against sexual minorities could continue to improve the rate of individuals who initiate PrEP use.

Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.

Despite nearly one-third of reversible dementia cases being drug induced, cognitive safety is a neglected aspect of clinical trials.